UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2025

LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-36569**	**35-2318913**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

201 Burlington Road, South Building
Bedford, Massachusetts 01730
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (978) 671-8001

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	LNTH	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Sale and Purchase Agreement

On January 12, 2025, Lantheus Medical Imaging, Inc., a Delaware corporation ("***Lantheus Medical***"), a subsidiary of Lantheus Holdings, Inc. ("***Lantheus***" or the "***Company***"), and Lantheus Radiopharmaceuticals UK Limited, a private limited liability company incorporated under the laws of England (the "***Purchaser***"), entered into a Sale and Purchase Agreement (the "***Agreement***") with Life Medical Group Limited, a private limited liability company incorporated under the laws of England (the "***Seller***"), and Life Healthcare Group Holdings Limited, a public limited liability company incorporated under the laws of South Africa ("***Life Healthcare Group Holdings***"), pursuant to which the Purchaser will acquire the entire issued share capital of Life Molecular Imaging Limited ("***Life Molecular***") (the "***Transaction***"). Lantheus Medical is acting as the Purchaser's guarantor under the Agreement.

Under the terms of the Agreement, Purchaser will pay an upfront amount of $350 million, payable in cash at closing and subject to customary adjustments, and potential additional net sales earnout and milestone payments in an aggregate additional cash amount of up to $400 million. In addition, the Purchaser will assume in part, the obligation to make payments towards the Seller's retained future contingent liabilities under certain contractual arrangements, up to a value of $30 million.

For a period following the closing of the Transaction, the Purchaser has also agreed to use commercially reasonable efforts to grow Neuraceq and develop and seek regulatory approval for additional assets in Life Molecular's pipeline.

In connection with and within 60 business days of closing of the Transaction, Life Healthcare Group Holdings and the Purchaser intend to enter into an agreement pursuant to which the Purchaser would grant to Life Healthcare Group Holdings the right to opt into an exclusive license in South Africa to the intellectual property and technologies relating to products in Life Molecular's pipeline (including Neuraceq) acquired by Lantheus in the Transaction.

The Agreement contains customary representations, warranties and covenants by each of the applicable parties to the Agreement. In addition, the Seller has agreed to indemnify the Purchaser for certain tax claims. The representations, warranties and covenants in the Agreement were made solely for the benefit of the parties to the Agreement and may be subject to limitations agreed upon by the contracting parties. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures.

The Transaction is subject to customary closing conditions, including (a) approval of the Transaction by Life Healthcare Group Holdings' shareholders, (b) the regulatory clearances or expiration of applicable waiting periods under antitrust laws and foreign investment laws, (c) the Financial Surveillance Department of the South African Reserve Bank having granted approval in terms of the Exchange Control Regulations, and (d) the obtainment of certain third-party consents in connection with the Transaction. There are customary closing deliverables required in respect of the Transaction. If obligations in respect of such deliverables are not met, the parties have the ability to defer closing, and if closing has still not taken place following such deferral, to terminate the Agreement.

The Agreement contains customary non-solicitation covenants that prohibit Life Healthcare Group Holdings from soliciting competing proposals or entering into discussions concerning, or providing confidential information in connection with, certain proposals for an alternative transaction, subject to customary exceptions and applicable law. In the event that the directors of Life Healthcare Group Holdings (i) do not recommend to the shareholders of Life Healthcare Group Holdings that they vote to approve the Agreement or (ii) change their recommendation to approve the Agreement, in each case, if the approval of the Transaction by Life Healthcare Group Holdings' shareholders has not been obtained, the Seller would be required to pay the Purchaser a fee of $5 million.

The Agreement provides for certain termination rights for both the Seller and the Purchaser, including a right to terminate the Agreement if the closing conditions have not been satisfied or waived on or prior to December 31, 2025. If all conditions other than the obtainment of requisite regulatory approvals have been satisfied by December 31, 2025

and either party terminates the Agreement in accordance with its terms, the Purchaser would be required to pay the Seller a fee of $20 million. If all conditions other than the obtainment of certain required third-party consents have been satisfied by December 31, 2025 and either party terminates the Agreement in accordance with its terms, the Seller would be required to pay the Purchaser a fee of $20 million.

There can be no assurance that the Transaction will occur subject to the terms described herein, or at all. Even if the parties consummate the Transaction, the Company may not be able to achieve the expected benefits of the Transaction including, but not limited to, the increase in and diversification of its revenue and operating earnings from sales of Neuraceq, the commercialization of other products acquired from Life Molecular, if approved, expansion of research and development capabilities and integration of Life Molecular's commercial infrastructure.

The Transaction is anticipated to be completed in the second half of 2025.

The foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2024.

Item 7.01 Regulation FD Disclosure.

On January 13, 2025, the Company issued a press release announcing the signing of the Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto.

A copy of the Company's investor presentation relating to the Transaction is furnished as Exhibit 99.2 hereto.

The information in this item and Exhibits 99.1 and 99.2 are not deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), nor shall this item, Exhibit 99.1 or Exhibit 99.2 be incorporated by reference into the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such future filing.

Safe Harbor for Forward-Looking and Cautionary Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "target," "contemplate," "estimate," "predict," "potential," "opportunity," "creates" and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including the expected timing of the closing of the transaction; the ability of the parties to complete the Transaction considering the various closing conditions; the expected benefits of the transaction, such as efficiencies, cost savings, synergies, revenue growth, creating shareholder value, growth potential, market profile, enhanced competitive position, and financial strength and flexibility; the competitive ability and position of the Company following the Transaction; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Lantheus' plans, estimates or expectations could include, but are not limited to: (i) Life Healthcare Group Holdings may be unable to obtain shareholder approval as required for the Transaction; (ii) conditions to the closing of the Transaction may not be satisfied; (iii) the Transaction may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement of the Transaction on the ability of Lantheus or Life Healthcare Group to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Lantheus or Life Healthcare Group does business, or on Lantheus' or Life Molecular's operating results and business generally; (v) Lantheus' or Life Molecular's respective businesses may suffer as a result of uncertainty surrounding the Transaction and disruption of management's attention due to the Transaction; (vi) the outcome of any

legal proceedings related to the Transaction; (vii) Lantheus or Life Healthcare Group may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement; (ix) risks that the Transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the Transaction; (x) the risk that the Purchaser or the Seller may be unable to obtain governmental and regulatory approvals required for the Transaction, or that required governmental and regulatory approvals may delay the Transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed Transaction or cause the parties to abandon the proposed Transaction; (xi) risks that the anticipated benefits of the Transaction or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, competitive and technological changes; (xiii) expectations for future clinical trials, the timing and potential outcomes of clinical studies and interactions with regulatory authorities; and (xiv) other risks to the consummation of the Transaction, including the risk that the Transaction will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Lantheus are set forth in its filings with the Securities and Exchange Commission (the "SEC"), including Lantheus' most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at www.sec.gov. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that Lantheus files from time to time with the SEC. The forward-looking statements in this document speak only as of the date of these materials. Except as required by law, Lantheus assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated January 13, 2025
99.2	Investor Presentation, dated January 13, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS HOLDINGS, INC.

By: /s/ Daniel Niedzwiecki
Name: Daniel Niedzwiecki
Title: Chief Administrative Officer and General Counsel

Date: January 13, 2025

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease

Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities

Transaction expected to be accretive to adjusted EPS within the first 12 months

Company to host conference call on January 13, 2025, at 8:30 AM EST

BEDFORD, Mass., January 13, 2025 – Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Life Molecular Imaging Ltd. ("Life Molecular"), in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments. Life Molecular, a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"), is dedicated to advancing novel Positron Emission Tomography (PET) radiopharmaceutical diagnostics.

The acquisition is expected to immediately enhance Lantheus' near and long-term growth profile and establish a commercial Alzheimer's disease (AD) franchise with the addition of Neuraceq® (florbetaben F18 injection). Neuraceq is a globally approved[1], F-18 radioactive diagnostic agent indicated for PET imaging of the brain to estimate ß-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. Neuraceq can be used to confirm eligibility for new AD therapies. Life Molecular also provides robust R&D capabilities, a strong commercial infrastructure, and an established international presence, which Lantheus plans to utilize to accelerate the development, advancement, and commercialization of the combined company's pipeline. The transaction is expected to be accretive to Lantheus' Adjusted Earnings Per Share within 12 months of close.

"This acquisition aligns with our strategy to drive long-term growth and value creation by investing in high-potential, complementary assets and R&D capabilities to strengthen our radiopharmaceutical leadership," said Brian Markison, CEO of Lantheus. "This is a natural extension of our existing RM2 partnership, and we are ideally equipped to collectively grow Neuraceq and advance Life Molecular's diverse radiopharmaceutical assets. We are excited to welcome their exceptionally talented team, whose expertise will further enhance our capabilities in the development and commercialization of innovative radiodiagnostic solutions. With our combined resources and financial strength, we are well-positioned to deliver a meaningful impact for patients and clinicians worldwide."

[1] Neuraceq® is commercially approved in the United States, Canada, Europe, the UK, Switzerland, China, Japan, South Korea, and Taiwan.

“Life Healthcare is proud to have been the steward for Life Molecular and is pleased to have found a partner who recognizes the value of the business we have nurtured,” said Peter Wharton-Hood, Chief Executive of Life Healthcare. “We invested in LMI with the vision of developing solutions that can improve patient outcomes, and we are confident in Lantheus’ ability to accelerate its growth.”

Compelling Strategic and Financial Rationale

- **Establishes Commercial Franchise in AD**: The acquisition of Life Molecular adds commercial AD radiodiagnostic capabilities and infrastructure, including a manufacturing network and go-to-market experience that will complement Lantheus’ existing capabilities and can be used to launch future AD assets.
- **Expands Growth Profile with Approved AD Radiodiagnostic**: The acquisition of Neuraceq, a globally marketed radioactive agent that assists in diagnosing cognitive impairments, including AD and dementia, is expected to accelerate Lantheus’ revenue growth. With the combined company’s operational and commercial expertise, Lantheus expects to maximize access to Neuraceq for the approximately 55 million people around the world who are living with AD or mild cognitive impairment.
- **Enhances R&D and Clinical Development Capabilities**: Life Molecular brings high-caliber research and pharmaceutical development capabilities that enhance and complement Lantheus’ resources, strengthening the Company’s potential to advance its diverse pipeline.
- **Complements Innovative Radiodiagnostic Pipeline:** The acquisition complements Lantheus’ pipeline with the addition of highly complementary radiodiagnostic clinical-stage assets targeting diseases with significant unmet needs.

This transaction builds on Lantheus’ June 2024 acquisition of the global rights to LMI’s clinical-stage radiotherapeutic and radiodiagnostic pair, 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target gastrin-releasing peptide receptor (GRPR) for prostate, breast and other cancers. This theranostic pair strengthened Lantheus’ oncology pipeline and will potentially allow the Company to enter new disease areas.

Additional Transaction Details

Under the terms of the agreement between Lantheus Medical Imaging, Inc. (“Lantheus Medical”), Lantheus Radiopharmaceuticals UK Limited (the “Lantheus UK”), Life Medical Group Limited (the “Seller”), and Life Healthcare Group Holdings Limited (“Life Healthcare”), Lantheus UK will pay an upfront amount of $350 million, payable in cash at closing, and potential additional net sales earnout and milestone payments in an aggregate additional cash amount of up to $400 million. In addition, Lantheus UK may pay up to $30 million towards Seller’s retained future contingent liabilities under certain contractual arrangements. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second half of 2025, subject to customary closing conditions, including the approval of Life Healthcare Group Holdings’ shareholders and regulatory clearances or expiration of applicable waiting periods under antitrust laws and foreign investment laws, and the Financial Surveillance Department of the South African Reserve Bank having granted approval under Exchange Control Regulations.

Advisors

RMB, a division of FirstRand Bank Limited, acted as financial advisor to Life Healthcare in this transaction and A&O Shearman LLP and Cliffe Dekker Hofmeyr Inc. acted as legal advisors.

Morgan Stanley acted as financial advisor to Lantheus in this transaction, while Covington & Burling LLP, Ropes & Gray LLP and Bowmans acted as legal advisors and Ernst & Young LLP acted as financial and tax advisor.

Conference Call and Webcast Details

Lantheus will hold a conference call on Monday, January 13, 2025, at 8:30 AM EST. To access the live conference via webcast, please register here. A replay will be available after the conclusion of the call on Lantheus' investor website at: https://investor.lantheus.com/news-events/calendar-of-events.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Neuraceq (florbetaben F18 injection)

Indication

Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ß-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations of Use

- A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder.
- Safety and effectiveness of Neuraceq have not been established for:
  - Predicting development of dementia or other neurologic conditions
  - Monitoring responses to therapies.

Important Safety Information

Risk for Image Interpretation and Other Errors

Errors may occur in the Neuraceq estimation of brain neuritic ß-amyloid plaque density during image interpretation. Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of

the presence of brain neuritic ß-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic ß-amyloid plaques in the future.

Radiation Risk

Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure.

Common Adverse Reactions

The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects. No serious adverse reactions related to Neuraceq administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema (1.7%), irritation (1.1%) and pain (3.4%).

For more information please visit: neuraceq.com.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

About Life Molecular Imaging (Life Molecular)

Life Molecular Imaging (Life Molecular) is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Life Molecular is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit https://life-mi.com.

About Life Healthcare

Life Healthcare is a global people-centered, diversified healthcare organization. Life Healthcare Group Holdings is listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The company also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative radiopharmaceuticals. Visit: https://www.lifehealthcare.co.za/

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The

inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "estimate," "expect," "may," "plan," "potential," "predict," "target," "will," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including the expected timing of the closing of the transaction; the ability of the parties to complete the transaction considering the various closing conditions; the expected benefits of the transaction, such as efficiencies, cost savings, synergies, revenue growth, creating shareholder value, growth potential, market profile, enhanced competitive position, and financial strength and flexibility; the competitive ability and position of the Company following the transaction; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Lantheus' plans, estimates or expectations could include, but are not limited to: (i) Life Healthcare Group Holdings may be unable to obtain shareholder approval as required for the transaction; (ii) conditions to the closing of the transaction may not be satisfied; (iii) the transaction may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement of the transaction on the ability of Lantheus or Life Healthcare Group to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Lantheus or Life Healthcare Group does business, or on Lantheus' or Life Molecular's operating results and business generally; (v) Lantheus' or Life Molecular's respective businesses may suffer as a result of uncertainty surrounding the transaction and disruption of management's attention due to the transaction; (vi) the outcome of any legal proceedings related to the transaction; (vii) Lantheus or Life Healthcare Group may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; (ix) risks that the transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the transaction; (x) the risk that Lantheus or the Seller may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xi) risks that the anticipated benefits of the transaction or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, competitive and technological changes; (xiii) expectations for future clinical trials, the timing and potential outcomes of clinical studies and interactions with regulatory authorities; and (xiv) other risks to the consummation of the transaction, including the risk that the transaction will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Lantheus are set forth in its filings with the Securities and Exchange Commission (the "SEC"), including Lantheus' most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at www.sec.gov. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that Lantheus files from time to time with the SEC. The forward-looking statements in this document speak only as of the date of these materials. Except as required by law, Lantheus assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Contacts:

Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com

Exhibit 99.2

LANTHEUS

Lantheus to Acquire Life Molecular Imaging

Accelerating Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

January 13, 2025

FIND. FIGHT. FOLLOW.

© 2025 Lantheus. All rights reserved.

Agenda

- Acquisition Overview & Strategic Rationale
- Transaction Summary
- Commercial Infrastructure and R&D Capabilities
- Growth Strategy
- Q&A

LANTHEUS

© 2025 Lantheus. All rights reserved.

Safe Harbor Statements

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "estimate," "expect," "may," "plan," "potential," "predict," "target," "will," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including the expected timing of the closing of the transaction; the ability of the parties to complete the transaction considering the various closing conditions; the expected benefits of the transaction, such as efficiencies, cost savings, synergies, revenue growth, creating shareholder value, growth potential, market profile, enhanced competitive position, and financial strength and flexibility; the competitive ability and position of the Company following the transaction; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Lantheus' plans, estimates or expectations could include, but are not limited to: (i) Life Healthcare Group Holdings may be unable to obtain shareholder approval as required for the transaction; (ii) conditions to the closing of the transaction may not be satisfied; (iii) the transaction may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement of the transaction on the ability of Lantheus or Life Healthcare Group to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Lantheus or Life Healthcare Group does business, or on Lantheus' or Life Molecular's operating results and business generally; (v) Lantheus' or Life Molecular's respective businesses may suffer as a result of uncertainty surrounding the transaction and disruption of management's attention due to the transaction; (vi) the outcome of any legal proceedings related to the transaction; (vii) Lantheus or Life Healthcare Group may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; (ix) risks that the transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the transaction; (x) the risk that Lantheus or the Seller may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xi) risks that the anticipated benefits of the transaction or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, competitive and technological changes; (xiii) expectations for future clinical trials, the timing and potential outcomes of clinical studies and interactions with regulatory authorities; and (xiv) other risks to the consummation of the transaction, including the risk that the transaction will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Lantheus are set forth in its filings with the Securities and Exchange Commission (the "SEC"), including Lantheus' most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at www.sec.gov. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that Lantheus files from time to time with the SEC. The forward-looking statements in this document speak only as of the date of these materials. Except as required by law, Lantheus assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

All trademarks, logos and service marks used in this presentation are the property of their respective owners.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; adjusted operating income and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company's reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

© 2025 Lantheus. All rights reserved.

Acquisition of Life Molecular Imaging (LMI) Delivers Compelling Strategic, Operational, and Financial Benefits

LANTHEUS + Life HEALTH CARE Molecular Imaging

Establishes commercial franchise in growing Alzheimer's disease (AD) / Dementia radio-diagnostic market

Expands growth profile with Neuraceq®, a globally-approved radiodiagnostic for AD

Enhances R&D and clinical capabilities to accelerate advancement of combined portfolio

Strengthens innovative radiodiagnostic pipeline with complementary clinical-stage assets

Accelerates entry into sizeable AD/Dementia radiodiagnostic market[1]

1, Data on file.

© 2025 Lantheus. All rights reserved.

Life Molecular Imaging: Established Radiopharmaceutical Player

International, commercial-stage radiopharmaceutical company, with globally-approved product (Neuraceq), commercial infrastructure, and promising pipeline/R&D expertise

- Pipeline of radiodiagnostics
- US AD commercial presence
- Advanced, complementary manufacturing processes
- Established clinical infrastructure in Europe
- Talented R&D and commercial team

2012	2014	2018	2024
Spin-out from Bayer, becomes Piramal Enterprises Ltd	NEURACEQ® approved (US & EU)	LMI acquired by Life Healthcare	June 2024: LMI out-licenses global RM2 rights to Lantheus

NeuraCeq® florbetaben F18 injection | **A Global Brand[1]**

Favorable relationships with manufacturers, hospitals, imaging centers, and neurologists across key markets



1, Neuraceq® is commercially approved in the United States, Canada, Europe, the UK, Switzerland, China, Japan, South Korea and Taiwan. Neuraceq is supplied to Australia on a named patient basis; Chile according to local legislation and Brazil by simplified notification scheme.

LANTHEUS

© 2025 Lantheus. All rights reserved.

Transaction Summary

Overview

Acquiring Life Molecular Imaging from Life Healthcare (LHC.JO)

ALL CASH, DEBT-FREE TRANSACTION
with upfront payment of $350 million, payable in cash at closing

Up to $400 million in potential earn-out and milestone payments

Up to $30 million towards LHC's retained future contingent liabilities under certain contractual arrangements

LMI stockholders provided with immediate and certain value and mutually beneficial sharing of upside

Compelling Financial Rationale

- **Anticipated to drive an increase in consolidated, organic annual revenue growth** by approximately 200 to 300 basis points over the next three years
- **Expected to be accretive to Lantheus' Adjusted Earnings Per Share** within 12 months post close
- **Expected to support Lantheus' near-term sales growth** with the addition of Neuraceq, while also expanding our international footprint

Timing and Approvals

Anticipated to close in the second half of 2025, subject to customary closing conditions, including the approval of Life Healthcare Group shareholders and regulatory clearances

© 2025 Lantheus. All rights reserved.

ESTABLISHES Commercial Franchise

LANTHEUS — Operational and commercial expertise

Life Molecular Imaging — Existing and complementary AD capabilities

POSITIONED TO EXPAND
Neuraceq access to millions of Alzheimer's patients around the world

New Late-Stage Pipeline Programs

1. **18F-PI-2620** (Phase 3) — LMI's radiodiagnostic tau agent, complementary to MK-6240, our Phase 3 tau diagnostic
2. **Neuraceq LCM** (Phase 3) — Detection of cardiac amyloidosis

Potential to provide precise, real-time insights into function and pathology

critical for **diagnosis, staging, treatment planning, and ultimately, patient outcomes**

© 2025 Lantheus. All rights reserved.

Remarkable Market Growth in Alzheimer's Diagnostics

National Institute on Aging | **Alzheimer's Association** | **SNMMI**

RECOMMEND

Amyloid- and tau-PET imaging

for diagnosis, staging, & treatment monitoring[1, 2]

Market Potential

U.S. AD PET radiodiagnostics TAM

USD Billions[3]

LMI Acquisition

Enhances research, manufacturing, and global commercialization

ADVANCING the Alzheimer's radiodiagnostic pipeline and **EXPANDING** market opportunities worldwide

Enhances Lantheus' ability to **FIND. FIGHT. FOLLOW® disease** to **deliver better patient outcomes**

LANTHEUS

1, G Rabinovici. J Nucl Med 2025; 00:1–27. 2. C Jack. Alzheimer's Dement. 2024;20:5143–5169; 3. Addressable market based on current management estimates and 3rd party market research.

© 2025 Lantheus. All rights reserved.

Transaction Supports Strategy and Long-Term Value Creation

Aligns with Lantheus' strategy to enhance our radiopharmaceutical leadership by expanding our capabilities, diversifying our business, and strengthening our long-term growth potential through inorganic actions

Enhances Radiopharmaceutical R&D Expertise

Adds Significant U.S. Commercial & International Infrastructure

Expands our Pipeline with Highly Complementary Clinical Assets

LMI's **innovative PET portfolio**

Lantheus' **operational and commercial expertise**

Unlocks the **full potential of our combined companies**

© 2025 Lantheus. All rights reserved.

Appendix

© 2025 Lantheus. All rights reserved.

Enhances Growth Profile with Approved Alzheimer's Disease Radiodiagnostic

NeuraCeq® florbetaben F18 injection

^{18}F-florbetaben is a selective, reversible, high-affinity binding amyloid-beta PET agent

- Indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline[1]
- Approved in USA, Canada, EU, UK, Switzerland, Japan, China, Taiwan & South Korea
- Available via Biomarker Solutions: used in 20+ therapeutic studies across 31 countries & large-scale consortium trials (IDEAS & AMYPAD)[2]

The Patient Diagnostic Journey with NEURACEQ

1. **INJECTION** — Patients referred by physician for amyloid PET scan are injected with NEURACEQ, a radioactive molecule that binds to amyloid proteins in brain
2. **45+ MINUTES** — Patient waits 45-130 minutes after injection, allowing time for NEURACEQ to locate and bind to amyloid proteins
3. **PET-CT SCAN** — During PET scan, patient lies down on scanner bed. NEURACEQ emits radiation, which can be detected by scanner
4. **RESULTS REVIEW** — After scan, radiologist / nuclear physician will review scan, write a report and send to patient's doctor
5. **TREATMENT** — If amyloid proteins are present, patients can potentially begin targeted treatment to reduce number of amyloid proteins in brain

NEURACEQ delivers significant value by **providing accurate, specific detection of amyloid plaques aiding in AD diagnosis –** enables patients to access disease-modifying drugs and medical support to reduce symptoms and improve condition

1. Neuraceq® prescribing information. Life Molecular Imaging; 2024; 2. La Joie et al. AAIC 2023, van Dyck et al. 2022, Sims et al. 2023, Bateman et al. 2023.

© 2025 Lantheus. All rights reserved.